PARIS, Feb. 28, 2011 /PRNewswire/ -- Cellectis bioresearch, a specialist in genome customization and subsidiary of Cellectis (Alternext: ALCLS), has today launched TALEN Access, the first fee-for-service custom TALEN(1).
Recognized as a pioneer in the development of innovative research products for genome customization, Cellectis bioresearch brings today the life sciences community a new tool for specifically modifying genes in any type of cell.
The service will start with the TALEN Access offer, which provides a pair of TALENs for 5,000 euro/US$, delivered in less than 3 weeks.
“What we are offering here is a true commercial revolution,” said Luc Selig, VP Sales and Marketing at Cellectis bioresearch. “We are keeping our promise to make genome customization affordable for the hundred of thousands academic research labs.”
For further information or to place orders, please go to www.cellectis-bioresearch.com/talen.
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on sequence specific nucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies.
The kits can be purchased online from www.cellectis-bioresearch.com. More information on the website.
About Cellectis
Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.
More information at www.cellectis.com.
Follow Cellectis on Twitter at www.twitter.com/cellectis.
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with the IPO and on which the French Autorite des marches financiers (“AMF”) granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
(1) TALEN: Transcription Activator-Like Effector Nuclease
SOURCE Cellectis bioresearch
